1 Supplementary Table S2. Binding affinities of botensilimab and parental IgG1 aCTLA-4

2 antibodies to human FcyRIIB, FcyRIIIA V158, and FcyRIIIA F158 proteins as determined by

3 surface plasmon resonance (SPR).

Human αCTLA-4	Binding affinity K _D (M)			A/I Ratio	
	FcγRIIIA (F158)	FcγRIIIA (V158)	FcγRIIB	FcγRIIIA (F158)/FcγRIIB	FcγRIIIA (V158)/FcγRIIB
Botensilimab	2.68 x 10 ⁻⁹	2.55 x 10 ⁻⁹	3.12 x 10 ⁻⁶	1164	1224
Parental IgG1	6.65 x 10 ⁻⁸	3.12 x 10 ⁻⁸	9.48 x 10 ⁻⁶	143	303

4 Equilibrium dissociation constant (KD) values were calculated from the kinetic rate constants (ka

5 and kd) obtained from the sensorgrams. The activating to inhibitory (A/I) ratio, defined as the ratio

6 of binding affinity of an IgG subtype to activating FcγRIIA relative to the inhibitory FcγRIB, is

7 presented for each antibody.